The global albumin market was valued at USD 7.9 billion in 2025 and is projected to reach USD 15.1 billion by the end of 2035, expanding at a compound annual growth rate (CAGR) of 7.5% during the forecast period (2026-2035). The growth of the market is attributed to a variety of factors, including the increasing demand for albumin in medical applications, advancements in biotechnology, and the rising global prevalence of diseases that require albumin treatments.

Albumin Industry Demand

Albumin is a vital protein found in human blood plasma, playing a critical role in regulating osmotic pressure and transporting substances throughout the body. It is commonly used in therapeutic settings, diagnostic procedures, and vaccine development. The albumin market primarily focuses on two types: human serum albumin (HSA), which is derived from human blood plasma, and recombinant albumin, which is produced using biotechnological methods.

The demand for albumin products has surged due to the increasing use of these proteins in various healthcare applications. The benefits of albumin, such as its cost-effectiveness, ease of administration, long shelf life, and availability, make it highly attractive for both healthcare providers and pharmaceutical companies. Additionally, the growing prevalence of chronic diseases such as liver cirrhosis, kidney failure, and burns, which require albumin-based treatments, has boosted the need for this product globally.

Request Sample @ https://www.researchnester.com/sample-request-5035

Albumin Market: Growth Drivers & Key Restraint

Growth Drivers –

Outsourcing of Manufacturing:
Many pharmaceutical companies and hospitals are increasingly outsourcing albumin production to specialized contract manufacturers due to cost efficiency and access to advanced technologies. This trend allows for more affordable and scalable production of albumin, contributing to market growth.
Prevalence of Chronic Diseases:
The rising incidence of chronic diseases like cirrhosis, kidney disease, and trauma is a significant driver for albumin-based treatments. Albumin helps manage fluid balance in patients, making it essential for critical care and post-surgery recovery.
Technological Advancements in Biotechnology:
Advancements in recombinant DNA technology have allowed for the production of high-quality recombinant albumin, which is increasing in demand. This innovation red

...

Posts

Wikitag Contributions

Comments